The Biostatistics Core Resource is a shared resource organized to meet the statistical needs of the USC/Norris Comprehensive Cancer Center (USC/NCCC) in the areas of study design, study monitoring, and data analysis. Statisticians in this Core Resource collaborate with investigators in all the Cancer Center programs - Molecular Genetics, Tumor Microenvironment, Epigenetics and Regulation, Developmental Therapeutics, Cancer Epidemiology, Cancer Control Research, Genitourinary Cancers, Gastrointestinal Cancers, Women's Cancers, and Hematologic and Viral-Associated Malignancies. The specific objectives are: 1. to provide statistical support to investigators at the USC/NCCC in the design, planning, conduct, analysis, and reporting of cancer research studies; 2. to ensure, by working with members of the Clinical Investigations Support Office (CISO) and the Clinical Research Informatics Core (CRIC), that clinical trials approved by the Clinical Investigations Committee (CIC) are properly executed and provide high quality clinical and translational research data;by working with the Translational Pathology Core (TPC) and CRIC, to support and maintain disease-based databases and associated tumor banks which serve as a resource for translational research;and 3. to adapt and incorporate, or develop, innovations in statistical and clinical trials methodology into the design and analysis of cancer research studies. Partia support is requested for six senior statisticians who have broad training and experience with the statistical methodology required by the research programs of the Cancer Center and have a proven record of successful collaborations and interactions with investigators from diverse fields. Partial support for three master's level statisticians is also requested to assist the senior statisticians of the Biostatistics Core Resource and to perform routine analyses.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48

Showing the most recent 10 out of 842 publications